查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1529839

CRO 体内肿瘤学市场规模、份额和趋势分析报告：按适应症、地区、细分市场预测，2024-2030 年

Oncology Based In-vivo CRO Market Size, Share & Trends Analysis Report By Indication (Blood Cancer, Solid Tumor, Others), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

体内肿瘤学市场成长与 CRO 趋势：

Grand View Research, Inc. 的最新报告显示，到 2030 年，CRO 体内肿瘤学的全球市场规模预计将达到 23.7 亿美元。

预计该市场在预测期内将以 8.58% 的复合年增长率成长。研发活动外包的增加、对先进药物的高需求以及 CRO 对国际标准的采用是推动市场成长的主要因素。

此外，专利到期导致的竞争加剧、学名药的快速成长以及生物相似药的推出等压力正促使製药公司寻求 CRO 援助。因此，可以预测，基于肿瘤的体内CRO产业在预测期内可能会出现良好的成长。

用于招募和沟通市场参与企业的行动创新、基于网路的生命科学实验室以及用于执行例行测试的机器人实验室等技术进步可能代表着市场机会。在全球范围内，外包是寻求进入新市场的赞助商和製药公司的解决方案。辉瑞和GlaxoSmithKline Plc等领先製药公司已成功与当地 CMO 和 CRO 合作，帮助外国公司实现在新兴国家的行销、监管和製造目标。

此外，该行业不断增加的合併和联盟预计将在未来几年扩大市场。例如，2023 年 1 月，分析解决方案公司 Bruker 收购了总部位于瑞士的临床前 CRO Biogenesis，以扩大其临床前能力。

CRO 市场的体内肿瘤学报告亮点

  • 固体癌市场占比最大，达47.4%。这是因为癌症的发生率在世界各地不断增加，世界卫生组织等全球组织对分析癌症发生率、致病因素和治疗方法的兴趣也越来越大，我们对此表示支持。
  • 在固体癌的模型中，患者来源的异质骨移植预计在预测期内的复合年增长率将达到 9.21%。
  • 2023年，北美地区将占据全球最大份额，达到49.97%，美国将做出主要贡献。这激发了研究活动的活力。大型製药企业和生命科学公司已在该地区建立业务，并继续推动市场成长。
  • 预计亚太地区在预测期内复合年增长率最快。这是由于许多新兴国家在亚太地区进行投资以及受监管市场根据全球平台进行各种修订来改变临床试验的评估标准。

目录

第一章调查方法和范围

第 2 章执行摘要

第 3 章 CRO 体内肿瘤学市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • CRO 体内肿瘤学市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析
    • COVID-19 影响分析
    • 主要交易及策略联盟分析

第四章 CRO 体内肿瘤学市场：按适应症的估计和趋势分析

  • CRO 体内肿瘤学市场，依适应症划分：细分仪表板
  • CRO 体内肿瘤学市场，依适应症划分：变异分析
  • 市场估计与预测：按指标划分，2018-2030 年

第五章 CRO 体内肿瘤学市场：区域估计与趋势分析

  • 2023 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 全球区域市场概述
  • 北美洲
    • 2018-2030 年市场估计与预测
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第六章 竞争状况

  • 市场参与企业分类
    • 创新者
    • 市场领导者
    • 新兴玩家
    • 2023 年企业市场占有率分析
  • 公司简介
    • Charles River Laboratory（CRL）
    • ICON Plc
    • Thermo Fisher Scientific Inc.
    • Eurofins Scientific
    • Taconic Biosciences
    • Crown Bioscience
    • Lab Corp
    • WuXi AppTec
    • EVOTEC
    • The Jackson Laboratory
Product Code: GVR-1-68038-859-6

Oncology Based In-vivo CRO Market Growth & Trends:

The global oncology based in-vivo CRO market size is expected to reach USD 2.37 billion by 2030, according to a new report by Grand View Research, Inc. The market is anticipated to grow at a CAGR of 8.58% over the forecast period. An increase in outsourcing of R&D activities, high demand for advanced medicines, and implementation of international standards by CROs are key factors driving the market growth.

Furthermore, the pressure from increasing competition due to patent expirations, the rapid growth of generics, and the introduction of biosimilar equivalents are propelling pharmaceutical companies to seek the aid of such organizations. Hence, it can be predicted that the oncology-based in-vivo CRO industry may witness lucrative growth over the forecast period.

Technological advancements such as mobile-enabled innovations for recruiting and communicating with participants, web-based life science labs and robotics labs to perform routine tests can be the opportunities of the market. At a global level, outsourcing is one of the solutions for sponsors and pharma companies seeking to make an entry into a new market. Big pharma companies such as Pfizer and GlaxoSmithKline partner with local CMOs and CROs, which have been successful in enabling foreign companies to achieve marketing, regulatory, and manufacturing goals in emerging economies.

Furthermore, an increase in the number of mergers and collaborations in this industry is expected to expand the market in the coming years. For instance, in January 2023, Bruker, an analytical solutions company, acquired a preclinical Switzerland-based CRO Biogenesis to expand its capabilities in preclinical activities.

Oncology Based In-vivo CRO Market Report Highlights:

  • The solid tumors segment held the largest share of 47.4% owing to the increasing incidence of cancer across the globe, and the growing interest of world agencies such as the WHO in analyzing their prevalence, causative agents, and treatment options is boosting R&D
  • Based on solid tumor-based model, patient-derived xenograft is anticipated to register the fastest CAGR of 9.21% over the forecast period
  • North America accounted for the largest global share of 49.97% in 2023, with the major contributions from the U.S., owing to increased funding available in the region. This has boosted research activities. Major pharmaceutical and life sciences companies continue to drive market growth with their established presence in the region
  • Asia Pacific is anticipated to register the fastest CAGR over the forecast period, owing to many developed countries investing in Asia Pacific regions and the various amendments made by the regulatory market to change the clinical trials evaluation standards according to the global platform

Table of Contents

Chapter 1. Research Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Indication
  • 1.3. Regional Scope
  • 1.4. Estimates And Forecast Timeline
  • 1.5. Objectives
    • 1.5.1. Objective-1
    • 1.5.2. Objective-2
    • 1.5.3. Objective-3
  • 1.6. Research Methodology
  • 1.7. Information Procurement
    • 1.7.1. Purchased Database
    • 1.7.2. GVR's Internal Database
    • 1.7.3. Secondary Sources
    • 1.7.4. Primary Research
  • 1.8. Information Or Data Analysis
    • 1.8.1. Data Analysis Models
  • 1.9. Market Formulation & Validation
  • 1.10. Model Details
    • 1.10.1. Commodity Flow Analysis
    • 1.10.2. Parent Market Analysis
  • 1.11. List Of Secondary Sources
  • 1.12. List Of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Oncology Based In-vivo CRO Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Accelerating the time to market
      • 3.2.1.2. Economic efficiency
      • 3.2.1.3. Increasing mergers and collaborations
      • 3.2.1.4. Increasing outsourcing of R&D Activities
    • 3.2.2. Market Restraint Analysis
  • 3.3. Oncology Based In-vivo CRO Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat Of New Entrant
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis
    • 3.3.4. Major Deals & Strategic Alliances Analysis

Chapter 4. Oncology Based In-vivo CRO Market: Indication Estimates & Trend Analysis

  • 4.1. Oncology Based In-vivo CRO Market, By Indication: Segment Dashboard
  • 4.2. Oncology Based In-vivo CRO Market, By Indication: Movement Analysis
  • 4.3. Oncology Based In-vivo CRO Market Estimates & Forecasts, By Indication, 2018 - 2030
    • 4.3.1. Blood cancer
      • 4.3.1.1. Blood Cancer Market, 2018 to 2030 (USD Million)
      • 4.3.1.2. Syngeneic model
      • 4.3.1.2.1. Syngeneic model Market, 2018 to 2030 (USD Million)
      • 4.3.1.3. Patient-derived xenograft
      • 4.3.1.3.1. Patient derived xenograft Market, 2018 to 2030 (USD Million)
      • 4.3.1.4. Xenograft
      • 4.3.1.4.1. Xenograft Market, 2018 to 2030 (USD Million)
    • 4.3.2. Solid tumor
      • 4.3.2.1. Solid Tumor Market, 2018 to 2030 (USD Million)
      • 4.3.2.2. Syngeneic model
      • 4.3.2.2.1. Syngeneic model Market, 2018 to 2030 (USD Million)
      • 4.3.2.3. Patient derived xenograft
      • 4.3.2.3.1. Patient derived xenograft Market, 2018 to 2030 (USD Million)
      • 4.3.2.4. Xenograft
      • 4.3.2.4.1. Xenograft Market, 2018 to 2030 (USD Million)
    • 4.3.3. Others
      • 4.3.3.1. Others Market, 2018 to 2030 (USD Million)
      • 4.3.3.2. Syngeneic model
      • 4.3.3.2.1. Syngeneic model Market, 2018 to 2030 (USD Million)
      • 4.3.3.3. Patient derived xenograft
      • 4.3.3.3.1. Patient derived xenograft Market, 2018 to 2030 (USD Million)
      • 4.3.3.4. Xenograft
      • 4.3.3.4.1. Xenograft Market, 2018 to 2030 (USD Million)

Chapter 5. Oncology Based In-vivo CRO Market: Regional Estimates & Trend Analysis

  • 5.1. Regional Market Share Analysis, 2023 & 2030
  • 5.2. Regional Market Dashboard
  • 5.3. Global Regional Market Snapshot
  • 5.4. North America
    • 5.4.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
    • 5.4.2. U.S.
      • 5.4.2.1. Key Country Dynamics
      • 5.4.2.2. Competitive Scenario
      • 5.4.2.3. Regulatory Scenario
      • 5.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030
    • 5.4.3. Canada
      • 5.4.3.1. Key Country Dynamics
      • 5.4.3.2. Competitive Scenario
      • 5.4.3.3. Regulatory Scenario
      • 5.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030
    • 5.4.4. Mexico
      • 5.4.4.1. Key Country Dynamics
      • 5.4.4.2. Competitive Scenario
      • 5.4.4.3. Regulatory Scenario
      • 5.4.4.4. Mexico Market Estimates and Forecasts, 2018 - 2030
  • 5.5. Europe
    • 5.5.1. UK
      • 5.5.1.1. Key Country Dynamics
      • 5.5.1.2. Competitive Scenario
      • 5.5.1.3. Regulatory Scenario
      • 5.5.1.4. UK Market Estimates and Forecasts, 2018 - 2030
    • 5.5.2. Germany
      • 5.5.2.1. Key Country Dynamics
      • 5.5.2.2. Competitive Scenario
      • 5.5.2.3. Regulatory Scenario
      • 5.5.2.4. Germany Market Estimates and Forecasts, 2018 - 2030
    • 5.5.3. France
      • 5.5.3.1. Key Country Dynamics
      • 5.5.3.2. Competitive Scenario
      • 5.5.3.3. Regulatory Scenario
      • 5.5.3.4. France Market Estimates and Forecasts, 2018 - 2030
    • 5.5.4. Italy
      • 5.5.4.1. Key Country Dynamics
      • 5.5.4.2. Competitive Scenario
      • 5.5.4.3. Regulatory Scenario
      • 5.5.4.4. Italy Market Estimates and Forecasts, 2018 - 2030
    • 5.5.5. Spain
      • 5.5.5.1. Key Country Dynamics
      • 5.5.5.2. Competitive Scenario
      • 5.5.5.3. Regulatory Scenario
      • 5.5.5.4. Spain Market Estimates and Forecasts, 2018 - 2030
    • 5.5.6. Denmark
      • 5.5.6.1. Key Country Dynamics
      • 5.5.6.2. Competitive Scenario
      • 5.5.6.3. Regulatory Scenario
      • 5.5.6.4. Denmark Market Estimates and Forecasts, 2018 - 2030
    • 5.5.7. Sweden
      • 5.5.7.1. Key Country Dynamics
      • 5.5.7.2. Competitive Scenario
      • 5.5.7.3. Regulatory Scenario
      • 5.5.7.4. Sweden Market Estimates and Forecasts, 2018 - 2030
    • 5.5.8. Norway
      • 5.5.8.1. Key Country Dynamics
      • 5.5.8.2. Competitive Scenario
      • 5.5.8.3. Regulatory Scenario
      • 5.5.8.4. Norway Market Estimates and Forecasts, 2018 - 2030
  • 5.6. Asia Pacific
    • 5.6.1. Japan
      • 5.6.1.1. Key Country Dynamics
      • 5.6.1.2. Competitive Scenario
      • 5.6.1.3. Regulatory Scenario
      • 5.6.1.4. Japan Market Estimates and Forecasts, 2018 - 2030
    • 5.6.2. China
      • 5.6.2.1. Key Country Dynamics
      • 5.6.2.2. Competitive Scenario
      • 5.6.2.3. Regulatory Scenario
      • 5.6.2.4. China Market Estimates and Forecasts, 2018 - 2030
    • 5.6.3. India
      • 5.6.3.1. Key Country Dynamics
      • 5.6.3.2. Competitive Scenario
      • 5.6.3.3. Regulatory Scenario
      • 5.6.3.4. India Market Estimates and Forecasts, 2018 - 2030
    • 5.6.4. South Korea
      • 5.6.4.1. Key Country Dynamics
      • 5.6.4.2. Competitive Scenario
      • 5.6.4.3. Regulatory Scenario
      • 5.6.4.4. South Korea Market Estimates and Forecasts, 2018 - 2030
    • 5.6.5. Australia
      • 5.6.5.1. Key Country Dynamics
      • 5.6.5.2. Competitive Scenario
      • 5.6.5.3. Regulatory Scenario
      • 5.6.5.4. Australia Market Estimates and Forecasts, 2018 - 2030
    • 5.6.6. Thailand
      • 5.6.6.1. Key Country Dynamics
      • 5.6.6.2. Competitive Scenario
      • 5.6.6.3. Regulatory Scenario
      • 5.6.6.4. Thailand Market Estimates and Forecasts, 2018 - 2030
  • 5.7. Latin America
    • 5.7.1. Brazil
      • 5.7.1.1. Key Country Dynamics
      • 5.7.1.2. Competitive Scenario
      • 5.7.1.3. Regulatory Scenario
      • 5.7.1.4. Brazil Market Estimates and Forecasts, 2018 - 2030
    • 5.7.2. Argentina
      • 5.7.2.1. Key Country Dynamics
      • 5.7.2.2. Competitive Scenario
      • 5.7.2.3. Regulatory Scenario
      • 5.7.2.4. Argentina Market Estimates and Forecasts, 2018 - 2030
  • 5.8. MEA
    • 5.8.1. South Africa
      • 5.8.1.1. Key Country Dynamics
      • 5.8.1.2. Competitive Scenario
      • 5.8.1.3. Regulatory Scenario
      • 5.8.1.4. South Africa Market Estimates and Forecasts, 2018 - 2030
    • 5.8.2. Saudi Arabia
      • 5.8.2.1. Key Country Dynamics
      • 5.8.2.2. Competitive Scenario
      • 5.8.2.3. Regulatory Scenario
      • 5.8.2.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030
    • 5.8.3. UAE
      • 5.8.3.1. Key Country Dynamics
      • 5.8.3.2. Competitive Scenario
      • 5.8.3.3. Regulatory Scenario
      • 5.8.3.4. UAE Market Estimates and Forecasts, 2018 - 2030
    • 5.8.4. Kuwait
      • 5.8.4.1. Key Country Dynamics
      • 5.8.4.2. Competitive Scenario
      • 5.8.4.3. Regulatory Scenario
      • 5.8.4.4. Kuwait Market Estimates and Forecasts, 2018 - 2030

Chapter 6. Competitive Landscape

  • 6.1. Market Participant Categorization
    • 6.1.1. Innovators
    • 6.1.2. Market Leaders
    • 6.1.3. Emerging Players
    • 6.1.4. Company Market Share Analysis, 2023
  • 6.2. Company Profiles
    • 6.2.1. Charles River Laboratory (CRL)
      • 6.2.1.1. Company Overview
      • 6.2.1.2. Financial Performance
      • 6.2.1.3. Service Benchmarking
      • 6.2.1.4. Strategic Initiatives
    • 6.2.2. ICON Plc
      • 6.2.2.1. Company Overview
      • 6.2.2.2. Financial Performance
      • 6.2.2.3. Service Benchmarking
      • 6.2.2.4. Strategic Initiatives
    • 6.2.3. Thermo Fisher Scientific Inc.
      • 6.2.3.1. Company Overview
      • 6.2.3.2. Financial Performance
      • 6.2.3.3. Service Benchmarking
      • 6.2.3.4. Strategic Initiatives
    • 6.2.4. Eurofins Scientific
      • 6.2.4.1. Company Overview
      • 6.2.4.2. Financial Performance
      • 6.2.4.3. Service Benchmarking
      • 6.2.4.4. Strategic Initiatives
    • 6.2.5. Taconic Biosciences
      • 6.2.5.1. Company Overview
      • 6.2.5.2. Financial Performance
      • 6.2.5.3. Service Benchmarking
      • 6.2.5.4. Strategic Initiatives
    • 6.2.6. Crown Bioscience
      • 6.2.6.1. Company Overview
      • 6.2.6.2. Financial Performance
      • 6.2.6.3. Service Benchmarking
      • 6.2.6.4. Strategic Initiatives
    • 6.2.7. Lab Corp
      • 6.2.7.1. Company Overview
      • 6.2.7.2. Financial Performance
      • 6.2.7.3. Service Benchmarking
      • 6.2.7.4. Strategic Initiatives
    • 6.2.8. WuXi AppTec
      • 6.2.8.1. Company Overview
      • 6.2.8.2. Financial Performance
      • 6.2.8.3. Service Benchmarking
      • 6.2.8.4. Strategic Initiatives
    • 6.2.9. EVOTEC
      • 6.2.9.1. Company Overview
      • 6.2.9.2. Financial Performance
      • 6.2.9.3. Service Benchmarking
      • 6.2.9.4. Strategic Initiatives
    • 6.2.10. The Jackson Laboratory
      • 6.2.10.1. Company Overview
      • 6.2.10.2. Financial Performance
      • 6.2.10.3. Service Benchmarking
      • 6.2.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 North America Oncology Based In-vivo CRO market, by region, 2018 - 2030 (USD Million)
  • Table 4 North America Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 5 U.S. Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 6 Canada Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 7 Mexico Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 8 Europe Oncology Based In-vivo CRO market, by region, 2018 - 2030 (USD Million)
  • Table 9 Europe Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 10 UK Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 11 Germany Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 12 France Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 13 Italy Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 14 Spain Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 15 Denmark Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 16 Sweden Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 17 Norway Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 18 Asia Pacific Oncology Based In-vivo CRO market, by region, 2018 - 2030 (USD Million)
  • Table 19 Asia Pacific Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 20 Japan Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 21 China Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 22 India Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 23 South Korea Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 24 Australia Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 25 Thailand Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 26 Latin America Oncology Based In-vivo CRO market, by region, 2018 - 2030 (USD Million)
  • Table 27 Latin America Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 28 Brazil Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 29 Argentina Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 30 Middle East & Africa Oncology Based In-vivo CRO market, by region, 2018 - 2030 (USD Million)
  • Table 31 Middle East & Africa Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 32 South Africa Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 33 Saudi Arabia Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 34 UAE Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 35 Kuwait Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Oncology Based In-vivo CRO Market revenue, 2018 - 2030 (USD Million)
  • Fig. 10 Oncology Based In-vivo CRO Market snapshot
  • Fig. 11 Oncology Based In-vivo CRO Market driver impact
  • Fig. 12 Oncology Based In-vivo CRO Market restraint impact
  • Fig. 13 Oncology Based In-vivo CRO sector key takeaways (USD Million)
  • Fig. 14 Oncology Based In-vivo CRO Market: Type movement analysis
  • Fig. 15 Blood cancer market, 2018 - 2030 (USD Million)
  • Fig. 16 Syngeneic model market, 2018 - 2030 (USD Million)
  • Fig. 17 Patient derived xenograft market, 2018 - 2030 (USD Million)
  • Fig. 18 Xenograft market, 2018 - 2030 (USD Million)
  • Fig. 19 Solid tumor market, 2018 - 2030 (USD Million)
  • Fig. 20 Syngeneic model market, 2018 - 2030 (USD Million)
  • Fig. 21 Patient derived xenograft market, 2018 - 2030 (USD Million)
  • Fig. 22 Xenograft market, 2018 - 2030 (USD Million)
  • Fig. 23 Others market, 2018 - 2030 (USD Million)
  • Fig. 24 Syngeneic model market, 2018 - 2030 (USD Million)
  • Fig. 25 Patient derived xenograft market, 2018 - 2030 (USD Million)
  • Fig. 26 Xenograft market, 2018 - 2030 (USD Million)
  • Fig. 27 Regional marketplace: Key takeaways
  • Fig. 28 Regional outlook, 2023 & 2030
  • Fig. 29 North America Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 30 U.S. Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 31 Canada Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 32 Mexico Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 33 Europe Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 34 UK Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 35 Germany Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 36 France Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 37 Italy Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 38 Spain Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 39 Denmark Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 40 Sweden Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 41 Norway Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 42 Asia Pacific Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 43 Japan Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 44 China Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 45 India Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 46 South Korea Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 47 Australia Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 48 Thailand Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 49 Latin America Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 50 Brazil Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 51 Argentina Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 52 Middle East & Africa Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 53 South Africa Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 54 Saudi Arabia Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 55 UAE Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 56 Kuwait Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 57 Market participant categorization